In treatment-naive KRASG12C-mutated NSCLC, fulzerasib plus cetuximab showed encouraging activity with a favourable safety profile. The combination is currently being planned for investigation in a phase 3 study.
[Articles] Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial
The Lancet Oncology | | Vanesa Gregorc, Margarita Majem, Giuseppe Lo Russo, Michele Maio, Stephanie Salvagni, Vanesa Gutiérrez-Calderon, Maria Gonzalez-Cao, Sergio Sandiego Contreras, Anna Koumarianou, Alessandra Bearz, Reyes Bernabé-Caro, Santiago Viteri, Miguel Fernández de Sanmamed, Flora Zagouri, Teresa Morán Bueno, Chiara Lazzari, Sergio Martínez-Recio, Ana Giménez-Capitán, Yue Zhang, Yue Shan, Huaqiang Zhu, Congqiao Zhao, Haige Shen, Yu Wang, Rafael Rosell
Topics: lung-cancer, blood-cancer, clinical-trials, research